Immuneering Presents Design and Methodology of Phase 3 Trial
Immuneering presented the design and methodology of its ongoing Phase 3 MAPKeEPR 301 trial at the 2026 ESMO Congress.
Immuneering presented the design and methodology of its ongoing Phase 3 MAPKeEPR 301 trial at the 2026 ESMO Congress.